Answers are grounded in this paper and cite their sources.
Abstract ID 92316 Poster Board 281 Background: A variety of tryptamine-based psychedelics induce psychoactive effects in humans and animals that are mediated by serotonin 2A receptors (5-HT2A), but these compounds are generally non-selective and interact with other targets in the brain. For example, previous findings show that 4-hydroxy, 4-acetoxy- and 4-methoxy analogs of N-methyl-N-isopropyltryptamine (4-HO-MiPT, 4-AcO-MiPT, and 4-MeO-MiPT, respectively) interact with 5-HT transporters (SERT) in addition to acting as agonists at 5-HT2A. Here we studied the in vitro receptor profiles, in vitro monoamine transporter activities, and in vivo pharmacological effects of 4-HO-MiPT, 4-AcO-MiPT, and 4-MeO-MiPT. Methods: Receptor and transporter affinities were determined using a comprehensive binding screen where inhibition constants and functional activities were determined in vitro. Next, the ability of the compounds to block [³H]neurotransmitter uptake at the dopamine transporter (DAT), norepinephrine transporter (NET), and SERT was examined in rat brain synaptosomes and transporter-transfected cells. Inhibition constants for drug binding to serotonin 1A receptors (5-HT1A) and 5-HT2A were determined in mouse brain. Lastly, we compared the dose-related effects of acute subcutaneous 4-HO-MiPT, 4-AcO-MiPT, and 4-MeO-MiPT (0.03–30 mg/kg) on 5-HT2A-mediated head twitch responses (HTRs) in male C57BL/6J mice (n = 5 – 6/ dose) over 30 min test sessions. Videos of each session were analyzed using commercially available software. Locomotor activity and body temperature changes were also assessed. Results: The radioligand binding screen revealed that the MiPT analogs mainly targeted 5-HT receptors but also had notable inhibition constants at alpha-adrenergic receptors, sigma receptors, and SERT. Functional assays assessing Gαq-mediated calcium release showed the compounds act as fully efficacious 5-HT2A agonists (EC₅₀ range = 6–120 nM; Emax range = 90–102%), with reduced potency or efficacy at other 5-HT₂ subtypes. The compounds all displayed nM affinities at 5-HT2A (Ki range = 269–991 nM) in mouse brain, but only 4-MeO-MiPT displayed nM affinity at 5-HT1A (Ki = 347 nM). 4-MeO-MiPT also displayed potent and selective uptake inhibition at SERT (IC₅₀ = 57 nM) relative to the other two compounds (IC₅₀s = 423–1,398 nM) and cocaine (IC₅₀ = 326 nM). In mice, the compounds had similar potencies for inducing HTRs (ED₅₀ range = 0.75–0.97 mg/kg), with the rank order of 4-HO e 4-AcO e 4-MeO. Interestingly, 4-MeO-MiPT had reduced efficacy for inducing HTRs relative to the other compounds (Emax = 34 vs 77–80 HTRs/30 min). All compounds produced hypothermia (Emax = 4–7 °C) and hypolocomotion at the highest doses (i.e. 10 & 30 mg/kg). Conclusions: Overall, our data indicate that 4-position ring-substituted MiPT analogs interact mainly with 5-HT2A and other 5-HT receptors, but they also have relevant effects at non-receptor targets such as SERT. 4-MeO-MiPT displays potent SERT uptake inhibition and higher affinity for 5-HT1A when compared to its 4-HO and 4-AcO counterparts, which may underlie its reduced psychedelic-like effects in mice. Ongoing studies are evaluating the role of SERT and 5-HT1A in modulating the psychedelic-like effects of 4-MeO-MiPT to better understand the pharmacology of hybrid SERT uptake blocker/psychedelic tryptamines. This work was supported by a NIDA IRP grant to M.H.B. (DA-000522-16) and a collaborative research and development agreement between NIDA IRP and CaaMTech.
No takes yet. Share an insight, caveat, or question.
Glatfelter et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: